Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Genitourinary Cancers
•
Bladder Cancer
•
Medical Oncology
•
Diabetes
•
Endocrinology
How do you manage enfortumab vedotin related DKA that is refractory to standard therapy (insulin, fluids, etc)?
Related Questions
Would you consider neoadjuvant immunotherapy in a patient with Lynch syndrome and urothelial cancer?
Under what circumstances would it be appropriate to offer trimodality therapy (TMT) in muscle-invasive bladder cancer with localized variant histology?
What is your approach to muscle-invasive bladder cancer in a patient who is ineligible for surgery and radiotherapy?
What is your approach to a patient with muscle invasive bladder cancer getting neoadjuvant gemcitabine/cisplatin who develops significant ototoxicity due to cisplatin after two cycles?
Would you add pembrolizumab to enfortumab to further treat a patient with metastatic bladder cancer that progressed on avelumab maintenance after cis/gem?
How do you manage dysgeusia from Enfortumab Vedotin?
How would you approach adjuvant therapy in MIBC with predominantly squamous cell differentiation?
How do you decide between internal versus external decompression of malignant obstruction of the ureter (MUO)?
What is the optimal approach to systemic therapy for metastatic squamous cell carcinoma of the bladder considering the approval of enfortumab vedotin plus pembrolizumab for metastatic urothelial carcinoma?
Do you offer neoadjuvant chemotherapy to nested variant urothelial carcinoma (NVUC) of the bladder?
